5-Hydroxytryptamine1B/1D and 5-hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse trigeminal nucleus caudalis

Cephalalgia

Volumn 22, Issue 5, 2002, Pages 384-394

  Mitsikostas, Dimos D ^a,b   Sanchez Del Rio, M ^a,c   Waeber, C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ATHENS NAVAL HOSPITAL   (Greece)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

5 HT1B 1D receptors; 5 HT1F receptors; c fos; Migraine; Trigeminal pain

Indexed keywords

CAPSAICIN; CHLORALOSE; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; PROTEIN C FOS; SEROTONIN 1 AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SUMATRIPTAN; URETHAN; ANESTHETIC AGENT; CARBAZOLE DERIVATIVE; FLUOROBENZENE; NERVE PROTEIN; SEROTONIN AGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; GENE EXPRESSION; IMMUNOREACTIVITY; LATERAL RETICULAR NUCLEUS; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; RECEPTOR INTRINSIC ACTIVITY; SOLITARY TRACT NUCLEUS; TRIGEMINAL NUCLEUS; ADRENERGIC SYSTEM; ANIMAL; ANIMAL MODEL; AREA POSTREMA; BIOSYNTHESIS; BRAIN STEM; CISTERNA MAGNA; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; HEMODYNAMICS; INJECTION; METABOLISM; ONCOGENE; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANESTHETICS, GENERAL; ANIMALS; AREA POSTREMA; BRAIN STEM; CAPSAICIN; CARBAZOLES; CHLORALOSE; CISTERNA MAGNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROBENZENES; GENE EXPRESSION REGULATION; GENES, FOS; HEMODYNAMIC PROCESSES; INJECTIONS; MALE; MICE; MODELS, ANIMAL; NERVE TISSUE PROTEINS; PAIN; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN; SYNAPTIC TRANSMISSION; TRIGEMINAL CAUDAL NUCLEUS; URETHANE; VASOMOTOR SYSTEM;

EID: 0036597748     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2002.00382.x     Document Type: Article

References (48)

1. Mayberg MR, Zervas NT, Moskowitz MA. Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry. J Comp Neurol 1984; 223:46-56.
2. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993; 43:S16-S20.
3. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 1988; 8:83-91.
4. Mitsikostas DD, Sanchez DR. Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine. Brain Res Brain Res Rev 2001; 35:20-35.
5. Sheng M, Greenberg ME. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron 1990; 4:477-85.
6. Hunt SP, Pini A, Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 1987; 328:632-4.
7. Nozaki K, Boccalini P, Moskowitz MA. Expression of c-fos-like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space. Neuroscience 1992; 49:669-80.
8. Cutrer FM, Moussaoui S, Garret C, Moskowitz MA. The non-peptide neurokinin-1 antagonist, RPR 100893, decreases c-fos expression in trigeminal nucleus caudalis following noxious chemical meningeal stimulation. Neuroscience 1995; 64:741-50.
9. Mitsikostas DD, Sanchez del Rio R, Waeber C, Moskowitz MA, Cutrer FM. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 1998; 76:239-48.
10. Uhl GR, Walther D, Nishimori T, Buzzi MG, Moskowitz MA. Jun B, c-jun, jun D and c-fos mRNAs in nucleus caudalis neurons: rapid selective enhancement by afferent stimulation. Brain Res Mol Brain Res 1991; 11:133-41.
11. Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ. Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res 1993; 629:95-102.
12. Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992; 106:409-15.
13. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993; 109:788-92.
14. Mitsikostas DD, Sanchez del Rio R, Waeber C, Huang Z, Cutrer FM, Moskowitz MA. Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol 1999; 127:623-30.
15. Cutrer FM, Limmroth V, Ayata G, Moskowitz MA. Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol 1995; 116:3199-204.
16. 1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur J Pharmacol 1999; 369:271-7.
17. Sidman RL, Angevine JB, Pierce ET. Atlas of the mouse brain and spinal cord. New York: Harvard University Press, 1971.
18. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998; 79:964-82.
19. Mineta Y, Eisenberg E, Strassman AM. Distribution of Foslike immunoreactivity in the caudal medullary reticular formation following noxious facial stimulation in the rat. Exp Brain Res 1995; 107:34-38.
20. Strassman AM, Mineta Y, Vos BP. Distribution of fos-like immunoreactivity in the medullary and upper cervical dorsal horn produced by stimulation of dural blood vessels in the rat. J Neurosci 1994; 14:3725-35.
21. Strassman AM, Vos BP. Somatotopic and laminar organization of fos-like immunoreactivity in the medullary and upper cervical dorsal horn induced by noxious facial stimulation in the rat. J Comp Neurol 1993; 331:495-516.
22. Cutrer FM, Mitsikostas DD, Ayata G, Sanchez del Rio M. Attenuation by butalbital of capsaicin-induced c-fos like immunoreactivity in trigeminal nucleus caudalis. Headache 1999; 39:697-704.
23. Hoskin KL, Bulmer DC, Goadsby PJ. Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci Lett 1999; 266:173-6.
24. Alexander SP, Peters JA. Receptor and ion channel nomenclature supplement. Trends Pharmacol Sci 1997; (Suppl.):1-84.
25. Hoyer D, Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997; 36:419-28.
26. Moskowitz MA, Mitsikostas DD. Serotonin's central action in migraine. Neurol Network Comm 1998; 2:232-5.
27. 1B/1D receptor: a central action in migraine? Ann Neurol 1998; 43:711-8.
28. 2B receptor antagonist. Br J Pharmacol 1999; 127:1075-82.
29. 1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol 1999; 128:1133-40.
30. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999; 372:49-56.
31. Bouchelet I, Cohen Z, Case B, Seguela P, Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996; 50:219-23.
32. 1B-immunoreactivity within the human trigeminocerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997; 17:833-42.
33. 1D beta' receptors. Eur J Pharmacol 1993; 242:75-82.
34. Lambert G, Michalicek J. Effect of antimigraine drugs on dural blood flows and resistances and the responses to trigeminal stimulation. Eur J Pharmacol 1996; 311:141-51.
35. 1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery. Br J Clin Pharmacol 2000; 49:126-31.
36. Cohen Z, Bouchelet I, Olivier A, Villemure JG, Ball R, Stanimirovic DB et al. Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. J Cereb Blood Flow Metab 1999; 19:908-17.
37. 1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 2000; 129:501-8.
38. 1F-receptor activation. Br J Clin Pharmacol 1999; 47:75-82.
39. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60:1259-87.
40. 1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 1997; 61:2117-26.
41. 1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur J Pharmacol 1998; 352:117-24.
42. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997; 8:2237-40.
43. Phebus LA, Johnson KW, Stengel PW, Lobb KL, Nixon JA, Hipskind PA. The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sci 1997; 60:1553-61.
44. 1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacology 1997; 36:83-91.
45. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46:157-203.
46. 1F receptor agonist LY334370. Cephalalgia 1999; 19:851-8.
47. 1F agonist, inhibits the central and peripheral projections of rat trigeminal sensory neurones. Soc Neuroscience 1998; 240: (Abstract).
48. 1F receptor agonist (SSOFRA) LY 334370. Cephalalgia 1999; 19:318 (Abstract).